Subset analyses on the association between DM2 and NHL, leukemia, and myeloma
| . | NHL . | Leukemia . | Myeloma . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies . | OR (95% CI) . | P . | I2 . | No. of studies . | OR (95% CI) . | P . | I2 . | No. of studies . | OR (95% CI) . | P . | I2 . | |
| Overall outcome | 21 | 1.22 (1.07-1.39) | < .001 | 79% | 11 | 1.22 (1.03-1.44) | .02 | 82% | 10 | 1.22 (0.98-1.53) | .08 | 79% |
| Study design | ||||||||||||
| Cohort | 11 | 1.21 (1.02-1.45) | .03 | 87% | 8 | 1.28 (1.06-1.55) | .01 | 83% | 7 | 1.17 (0.92-1.50) | .21 | 80% |
| Case-control | 10 | 1.24 (1.03-1.49) | .02 | 39% | 3 | 0.86 (0.69-1.09) | .21 | 0% | 3 | 1.41 (0.69-2.89) | .35 | 81% |
| Sex | ||||||||||||
| Male | 7 | 1.13 (0.96-1.34) | .13 | 63% | 5 | 1.27 (1.08-1.49) | .003 | 51% | 5 | 1.00 (0.89-1.12) | .99 | 7% |
| Female | 7 | 1.24 (0.97-1.58) | .09 | 43% | 3 | 1.10 (0.89-1.37) | .39 | 0% | 3 | 1.24 (0.79-1.92) | .35 | 12% |
| Geographic region | ||||||||||||
| United States | 7 | 1.05 (0.91-1.21) | .52 | 41% | 2 | 1.18 (1.11-1.25) | < .001 | 0% | 3 | 1.37 (0.79-2.37) | .27 | 56% |
| Asia | 3 | 1.74 (1.31-2.30) | < .001 | 0% | 1 | 1.62 (1.23-2.13) | .001 | 0% | 1 | 3.55 (0.94-13.4) | .06 | 0% |
| Europe | 11 | 1.24 (1.05-1.46) | .01 | 70% | 8 | 1.15 (0.90-1.48) | .26 | 83% | 6 | 1.15 (0.89-1.50) | .29 | 74% |
| . | NHL . | Leukemia . | Myeloma . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of studies . | OR (95% CI) . | P . | I2 . | No. of studies . | OR (95% CI) . | P . | I2 . | No. of studies . | OR (95% CI) . | P . | I2 . | |
| Overall outcome | 21 | 1.22 (1.07-1.39) | < .001 | 79% | 11 | 1.22 (1.03-1.44) | .02 | 82% | 10 | 1.22 (0.98-1.53) | .08 | 79% |
| Study design | ||||||||||||
| Cohort | 11 | 1.21 (1.02-1.45) | .03 | 87% | 8 | 1.28 (1.06-1.55) | .01 | 83% | 7 | 1.17 (0.92-1.50) | .21 | 80% |
| Case-control | 10 | 1.24 (1.03-1.49) | .02 | 39% | 3 | 0.86 (0.69-1.09) | .21 | 0% | 3 | 1.41 (0.69-2.89) | .35 | 81% |
| Sex | ||||||||||||
| Male | 7 | 1.13 (0.96-1.34) | .13 | 63% | 5 | 1.27 (1.08-1.49) | .003 | 51% | 5 | 1.00 (0.89-1.12) | .99 | 7% |
| Female | 7 | 1.24 (0.97-1.58) | .09 | 43% | 3 | 1.10 (0.89-1.37) | .39 | 0% | 3 | 1.24 (0.79-1.92) | .35 | 12% |
| Geographic region | ||||||||||||
| United States | 7 | 1.05 (0.91-1.21) | .52 | 41% | 2 | 1.18 (1.11-1.25) | < .001 | 0% | 3 | 1.37 (0.79-2.37) | .27 | 56% |
| Asia | 3 | 1.74 (1.31-2.30) | < .001 | 0% | 1 | 1.62 (1.23-2.13) | .001 | 0% | 1 | 3.55 (0.94-13.4) | .06 | 0% |
| Europe | 11 | 1.24 (1.05-1.46) | .01 | 70% | 8 | 1.15 (0.90-1.48) | .26 | 83% | 6 | 1.15 (0.89-1.50) | .29 | 74% |
DM2 indicates diabetes mellitus type 2; and NHL, non-Hodgkin lymphoma.